Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints

Published on 17 Apr 2024 on Market Watch

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatment...

Read the rest of the article

Start tracking your investments with Statfolio

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage Therap...

Insider Monkey via Yahoo Finance 1 May 2024

Investors in Sage Therapeutics, Inc. (NASDAQ:SAGE) had a good week, as its shares rose 2.7% to cl...

Simply Wall St. via Yahoo Finance 28 Apr 2024

Sage Therapeutics SAGE reported a loss of $1.80 per share in the first quarter of 2024, wider tha...

Zacks via Yahoo Finance 27 Apr 2024

Shares of Sage Pharmaceuticals SAGE dropped 19.6% on Wednesday after management shared topline re...

Zacks via Yahoo Finance 19 Apr 2024

Sage Therapeutics, Inc. (SAGE) is expected to deliver a year-over-year increase in earnings on hi...

Zacks via Yahoo Finance 19 Apr 2024

Sage Therapeutics Inc. has decided to halt work on an experimental drugs in Parkinson’s disease...

The Business Journals 18 Apr 2024

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Dat...

Benzinga via Yahoo Finance 17 Apr 2024

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge

Investing.com 17 Apr 2024

Sage Therapeutics shares dropped early Wednesday after the company said its experimental treatmen...

Market Watch 17 Apr 2024

Sage Therapeutics (SAGE) stock plummeted after the company's Phase 2 trial for Parkinson’s diseas...

Seeking Alpha 17 Apr 2024